Search

peptide leucine arginine
Authors
Polte, T.
Assembly
peptide
Entity
1. peptide (polymer), 18 monomers, 2137.569 Da Detail

LVRGCWTKSY PPKPCFVR


Formula weight
2137.569 Da
Source organism
Homo sapiens
Exptl. method
solution NMR
Refine. method
torsion angle dynamics, simulated annealing
Data set
assigned_chemical_shifts
Chem. Shift Complete
Sequence coverage: 100.0 %, Completeness: 64.8 %, Completeness (bb): 74.7 % Detail

Polymer type: polypeptide(L)

Total1H13C
All64.8 % (138 of 213)75.4 % (92 of 122)50.5 % (46 of 91)
Backbone74.7 % (65 of 87)97.1 % (33 of 34)60.4 % (32 of 53)
Sidechain60.1 % (86 of 143)67.0 % (59 of 88)49.1 % (27 of 55)
Aromatic13.8 % (4 of 29)13.3 % (2 of 15)14.3 % (2 of 14)
Methyl85.7 % (12 of 14)85.7 % (6 of 7)85.7 % (6 of 7)

1. entity

LVRGCWTKSY PPKPCFVR

Sample #1

Solvent system 90% H2O/10% D2O, Pressure 1 atm, Temperature 298 K, pH 3.5, Details pH 3.5 concentration 1mM


#NameIsotope labelingTypeConcentration
1H2Onatural abundance90 %
2D2Onatural abundance10 %
3peptidenatural abundance1 mM
Sample #2

Solvent system 100% D2O, Pressure 1 atm, Temperature 298 K, pH 3.5, Details pH 3.5 1mM


#NameIsotope labelingTypeConcentration
4D2Onatural abundance100 %
5peptidenatural abundance1 mM

Protein Blocks Logo
Calculated from 20 models in PDB: 2M3N, Strand ID: A Detail


Release date
2013-09-09
Citation
Therapeutic potential of the peptide leucine arginine as a new nonplant bowman-birk-like serine protease inhibitor
Rothemund, S., Sonnichsen, F.D., Polte, T.
J. Med. Chem. (2013), 56, 6732-6744, PubMed 23988198 , DOI 10.1021/jm4005362 ,
Related entities 1. peptide, : 1 : 1 : 4 entities Detail
Experiments performed 10 experiments Detail
NMR combined restraints 4 contents Detail
Keywords bowman birk inhibitor